Deccan Healthcar

Has Deccan Healthcar declared dividend?

No Dividend History Available

What is the technical trend for Deccan Healthcar?

As of May 15, 2025, Deccan Healthcare's trend is mildly bearish, influenced by daily moving averages, while weekly indicators show mixed signals, suggesting a cautious outlook.

As of 15 May 2025, the technical trend for Deccan Healthcare has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a bearish trend, while the weekly MACD and Bollinger Bands show a mildly bullish signal. The monthly indicators, including MACD and KST, remain bearish, suggesting underlying weakness. The RSI shows no signal on both weekly and monthly time frames, indicating a lack of momentum. Overall, the mixed signals across different time frames reflect a cautious outlook for the stock.

Who are the peers of the Deccan Healthcar?

Deccan Healthcar's peers include Jeevan Scienti., Centenial Surgic, Aspira Pathlab, N G Industries, Amkay Products, Bandaram Pharma, KMS Medisurgi, Medinova Diagno., and Tejnaksh Health. Centenial Surgic has the highest 1-year return at 39.83%, while Deccan Healthcar has the lowest at -42.18%.

Peers: The peers of Deccan Healthcar are Jeevan Scienti., Centenial Surgic, Aspira Pathlab, N G Industries, Amkay Products, Bandaram Pharma, KMS Medisurgi, Medinova Diagno., and Tejnaksh Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amkay Products, while Average management risk is found at Jeevan Scienti., N G Industries, KMS Medisurgi, and Bandaram Pharma, and the rest. Below Average management risk is noted at Centenial Surgic, Aspira Pathlab, Deccan Healthcar, Tejnaksh Health, and the rest. Growth is Excellent at Bandaram Pharma, Below Average at Jeevan Scienti., Centenial Surgic, Aspira Pathlab, N G Industries, Amkay Products, Deccan Healthcar, KMS Medisurgi, Tejnaksh Health, and the rest. Good capital structure is seen at Centenial Surgic, N G Industries, Amkay Products, Deccan Healthcar, KMS Medisurgi, and Tejnaksh Health, while Average capital structure is observed at Jeevan Scienti., Aspira Pathlab, and the rest, and Below Average at Bandaram Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Centenial Surgic at 39.83%, while the lowest is Deccan Healthcar at -42.18%. Deccan Healthcar's 1-year return is significantly lower than all its peers. Additionally, the peers with negative six-month returns include Deccan Healthcar, Bandaram Pharma, Aspira Pathlab, Tejnaksh Health, and N G Industries.

Who are in the management team of Deccan Healthcar?

As of March 2022, the management team of Deccan Healthcar includes Minto Gupta (Chairman & Managing Director), Meenakshi Gupta (Director), Ruchi Khattar (Independent Director), Kandlakunta Samhitha (Independent Director), and Ravi Ram Prasad (Director).

As of March 2022, the management team of Deccan Healthcar includes the following individuals:<BR><BR>1. Minto Gupta - Chairman & Managing Director<BR>2. Meenakshi Gupta - Director<BR>3. Ruchi Khattar - Independent Director<BR>4. Kandlakunta Samhitha - Independent Director<BR>5. Ravi Ram Prasad - Director<BR><BR>The team comprises a mix of executive and independent directors, with Minto Gupta serving as the Chairman and Managing Director.

What does Deccan Healthcar do?

Deccan Health Care Ltd is a micro-cap company in the healthcare services industry, reporting net sales of 208 Cr and a net profit of 1 Cr for March 2025. It has a market cap of INR 48 Cr and key financial metrics include a P/E ratio of 44.00 and a return on equity of 1.08%.

Overview: <BR>Deccan Health Care Ltd operates in the healthcare services industry and is classified as a micro-cap company.<BR><BR>History: <BR>Deccan Health Care Ltd was originally incorporated as a Public Limited Company in 1996. It underwent several status changes, becoming a Private Limited Company in 2009 and then reverting to a Public Company in 2017. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 208 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 1 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 48 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 44.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.02 <BR>Return on Equity: 1.08% <BR>Price to Book: 0.45 <BR><BR>Contact Details: <BR>Address: 247 2nd Flr Dwarakapuri Colony, Punjagutta Hyderabad Telangana : 500082 <BR>Tel: 91-040-40144508 <BR>Email: investors@deccanhealthcare.co.in <BR>Website: http://www.deccanhealthcare.co.in

Who are the top shareholders of the Deccan Healthcar?

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta with 14.46%, Focal Ventures Private Limited at 9.69%, and individual investors holding a combined 47.83%. There are no mutual funds or foreign institutional investors involved, and no pledged promoter holdings.

The top shareholders of Deccan Healthcar include Minto Purshotam Gupta, who holds the largest stake at 14.46%. Following him, Focal Ventures Private Limited is the highest public shareholder with a 9.69% ownership. Additionally, individual investors collectively hold 47.83% of the shares. There are no mutual funds or foreign institutional investors currently holding shares in the company, and there are no pledged promoter holdings.

How big is Deccan Healthcar?

As of 24th July, Deccan Health Care Ltd has a market capitalization of 49.00 Cr, with recent net sales of 75.06 Cr and a net profit of 1.15 Cr. The company's shareholder's funds are 96.91 Cr, and total assets amount to 108.05 Cr.

As of 24th July, Deccan Health Care Ltd has a market capitalization of 49.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 75.06 Cr and a Net Profit of 1.15 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 96.91 Cr and Total Assets of 108.05 Cr.

Are Deccan Healthcar latest results good or bad?

Deccan Health Care's latest results are positive, with a 6.70% increase in net sales and a 100% rise in net profit. However, despite these strong indicators, market analysts have issued a 'Strong Sell' recommendation, suggesting caution.

Deccan Health Care's latest results for the quarter ending June 2025 indicate a positive performance overall. The company reported its highest quarterly net sales to date, reaching Rs 22.14 crore, which reflects a growth of 6.70% compared to the previous quarter. Additionally, the net profit saw a remarkable increase of 100%, a significant turnaround from the previous quarter's decline.<BR><BR>The inventory turnover ratio has also improved, indicating that the company is effectively managing its inventory. This is a positive sign for operational efficiency. However, despite these encouraging financial indicators, MarketsMOJO has issued a 'Strong Sell' recommendation on the stock, which suggests some caution from market analysts.<BR><BR>In summary, while the financial results show strong growth and improved performance metrics, the market sentiment appears to be more cautious.

Is Deccan Healthcar overvalued or undervalued?

As of October 6, 2025, Deccan Healthcare's valuation has improved to attractive, indicating it is undervalued with a PE ratio of 42.12, an EV to EBITDA of 13.43, and a low EV to Book Value of 0.41, especially when compared to peers like Sun Pharma and Cipla.

As of 6 October 2025, the valuation grade for Deccan Healthcar has moved from fair to attractive, indicating a positive shift in its perceived value. The company appears to be undervalued, particularly when considering its current PE ratio of 42.12, an EV to EBITDA of 13.43, and a notably low EV to Book Value of 0.41. These ratios suggest that the market may not fully recognize the company's potential relative to its earnings and assets.<BR><BR>In comparison to its peers, Deccan Healthcar's valuation stands out; for instance, Sun Pharma has a PE ratio of 34.56 but is considered expensive, while Cipla, also rated attractive, has a significantly lower PE of 22.72. The PEG ratio of Deccan Healthcar is 0.00, which further emphasizes its undervaluation compared to peers like Divi's Lab, which is categorized as very expensive with a PEG of 1.78. Additionally, the company's stock has underperformed against the Sensex over various periods, which may contribute to its current attractive valuation status.

How has been the historical performance of Deccan Healthcar?

Deccan Healthcar has experienced fluctuating financial performance, with net sales increasing from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025, but operating profit and cash flow remain negative, indicating ongoing operational challenges. Total assets and liabilities have both risen to INR 124.93 crore by March 2025.

Answer:<BR>The historical performance of Deccan Healthcar shows a fluctuating trend in key financial metrics over the past several years.<BR><BR>Breakdown:<BR>Deccan Healthcar's net sales have shown a consistent increase from INR 33.17 crore in March 2022 to INR 75.06 crore in March 2025. However, the total operating income has mirrored this growth, reaching INR 75.06 crore in March 2025. The raw material cost has also risen significantly, from INR 3.98 crore in March 2022 to INR 40.89 crore in March 2025, indicating increased operational expenses. The total expenditure, excluding depreciation, has escalated from INR 27.83 crore in March 2022 to INR 71.91 crore in March 2025. Consequently, the operating profit (PBDIT) has seen a decline from INR 5.34 crore in March 2022 to INR 3.16 crore in March 2025. Profit before tax has also decreased from INR 0.54 crore in March 2022 to INR 1.63 crore in March 2025, while profit after tax has fluctuated, reaching INR 1.16 crore in March 2025, down from INR 0.32 crore in March 2022. The company's total assets have increased from INR 90.63 crore in March 2022 to INR 124.93 crore in March 2025, alongside total liabilities rising from INR 90.63 crore to INR 124.93 crore in the same period. Cash flow from operating activities has remained negative, with a cash flow of -6.00 crore in March 2025, reflecting ongoing challenges in cash generation despite a net cash inflow of 0.00 crore in the same year.

When is the next results date for Deccan Health Care Ltd?

The next results date for Deccan Health Care Ltd is 13 February 2026.

The next results date for Deccan Health Care Ltd is scheduled for 13 February 2026.

Should I buy, sell or hold Deccan Health Care Ltd?

Which are the latest news on Deccan Healthcar?

Why is Deccan Health Care Ltd falling/rising?

As of 26-Mar, Deccan Health Care Ltd's stock price is at 8.26, reflecting a 6.67% decrease and a significant decline of 35.22% over the past eight days. Despite positive quarterly results, the stock's long-term fundamentals and consistent underperformance have led to waning investor interest and a new 52-week low.

As of 26-Mar, Deccan Health Care Ltd's stock price is falling, currently at 8.26, which reflects a decrease of 0.59 or 6.67%. The stock has been on a downward trend, having lost 35.22% over the last eight days. This consistent decline is further evidenced by its performance over various periods, with a staggering 57.40% drop in the past year and a 72.20% decrease over the last three years compared to the benchmark Sensex, which has shown a positive return of 30.85% in the same timeframe.<BR><BR>Today, the stock hit a new 52-week low of Rs. 7.9, indicating significant investor concern. It has underperformed its sector by 8.56% today and is trading below all key moving averages, suggesting a lack of upward momentum. Additionally, investor participation has decreased, with delivery volume falling by 48.28% against the five-day average, further indicating waning interest in the stock.<BR><BR>Despite the company declaring positive results over the last four quarters, including a notable increase in profits by 95.7%, the weak long-term fundamental strength, as indicated by an average Return on Equity (ROE) of 1.43%, raises concerns among investors. The stock's valuation, while attractive compared to peers, does not seem to be enough to counteract the negative sentiment and consistent underperformance against benchmarks. These factors collectively contribute to the stock's ongoing decline.

Why is Deccan Health Care Ltd falling/rising?

As of 27-Mar, Deccan Health Care Ltd's stock price is at 7.32, reflecting a significant decline of -59.49% over the past year. Despite recent profit increases, the stock's long-term fundamentals and consistent underperformance against the sector and benchmark indices contribute to its bearish trend.

As of 27-Mar, Deccan Health Care Ltd's stock price is falling, currently at 7.32, which reflects a change of -0.94 or -11.38%. The stock has been on a downward trend, having lost value for the last nine consecutive days, resulting in a significant decline of -42.59% during this period. Additionally, the stock has underperformed against the sector by -10.51% today.<BR><BR>The stock's performance over various time frames shows a stark decline, with a -32.84% drop over the past week and a -45.86% decrease over the last month. Year-to-date, the stock has fallen by -50.57%, and over the past year, it has decreased by -59.49%. This consistent underperformance is compounded by the fact that it has also lagged behind the benchmark index, the Sensex, in each of the last three annual periods.<BR><BR>Investor participation appears to be declining as well, with a delivery volume of 41.97k on March 25, which is down by -5.16% compared to the five-day average. Furthermore, the stock is trading below its moving averages across various time frames, indicating a bearish trend.<BR><BR>Despite the company declaring positive results in the last four consecutive quarters, including a significant increase in profits, the overall weak long-term fundamental strength, highlighted by an average Return on Equity (ROE) of 1.43%, contributes to the stock's decline. The stock is also trading at a discount compared to its peers, but the persistent underperformance against the benchmark and the significant losses over the past year overshadow these positive factors.

Why is Deccan Health Care Ltd falling/rising?

As of 28-Mar, Deccan Health Care Ltd's stock price is at Rs. 7.32, reflecting a significant decline of -11.38% and a -42.59% drop over the last nine days. Despite recent positive quarterly results, the stock's long-term fundamentals are weak, contributing to its bearish trend and underperformance against benchmarks.

As of 28-Mar, Deccan Health Care Ltd's stock price is falling, currently at Rs. 7.32, which reflects a change of -0.94 or -11.38%. The stock has been on a downward trend, having lost -42.59% over the last nine days. This consistent decline is evident in its performance metrics, as the stock has underperformed significantly against the benchmark Sensex, with a -32.84% return over the past week and a -45.86% return over the past month.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, indicating a bearish trend. The recent trading activity shows a decrease in investor participation, with delivery volume falling by -5.16% compared to the five-day average. Furthermore, the stock reached a new 52-week low of Rs. 7.1 today, which adds to the negative sentiment surrounding it.<BR><BR>Despite the company reporting positive results in the last four consecutive quarters, including a significant increase in profits, the overall long-term fundamentals appear weak. The average Return on Equity (ROE) is low at 1.43%, and the stock has consistently underperformed against its benchmarks over the last three years. This combination of poor short-term performance, low investor interest, and weak long-term fundamentals contributes to the ongoing decline in Deccan Health Care Ltd's stock price.

Why is Deccan Health Care Ltd falling/rising?

As of 29-Mar, Deccan Health Care Ltd's stock price is at Rs. 7.32, reflecting a significant decline of -11.38% and a year-to-date drop of -50.57%. The stock's persistent underperformance, reduced investor interest, and weak long-term fundamentals contribute to its ongoing downward trend.

As of 29-Mar, Deccan Health Care Ltd's stock price is falling, currently at Rs. 7.32, reflecting a change of -0.94 (-11.38%). The stock has been on a downward trend, having lost -42.59% over the last nine days, and it has underperformed its sector by -10.51% today. The stock is also trading below its moving averages across various time frames, indicating a persistent decline in price momentum.<BR><BR>In terms of broader performance, the stock has experienced significant losses over various periods, including a -50.57% decline year-to-date and a -59.49% drop over the past year. This consistent underperformance is further highlighted by the stock's returns being significantly lower than the benchmark Sensex, which has only declined by -13.66% year-to-date.<BR><BR>Additionally, the stock hit a new 52-week low of Rs. 7.1 today, which contributes to the negative sentiment surrounding it. Investor participation has also decreased, with delivery volume falling by -5.16% against the 5-day average, suggesting a lack of interest from investors.<BR><BR>While the company has reported positive results in terms of profitability and has a low price-to-book value, these factors have not translated into stock price stability or growth. The weak long-term fundamental strength, indicated by an average Return on Equity (ROE) of 1.43%, and the stock's consistent underperformance against benchmarks over the last three years further exacerbate the situation. Overall, the combination of declining stock performance, reduced investor participation, and weak long-term fundamentals are key reasons for the falling stock price of Deccan Health Care Ltd.